Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

BACKGROUND: A 12-dose, once-weekly regimen of isoniazid and rifapentine (3HP) is effective in preventing tuberculosis (TB) among people living with HIV (PLHIV). We sought to identify potential barriers to and facilitators of acceptance and completion of 3HP treatment from the perspective of people l...

Descripción completa

Detalles Bibliográficos
Autores principales: Semitala, Fred C., Musinguzi, Allan, Ssemata, Jackie, Welishe, Fred, Nabunje, Juliet, Kadota, Jillian L., Berger, Christopher A., Katamba, Achilles, Kiwanuka, Noah, Kamya, Moses R., Dowdy, David, Cattamanchi, Adithya, Katahoire, Anne R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247167/
https://www.ncbi.nlm.nih.gov/pubmed/34193311
http://dx.doi.org/10.1186/s43058-021-00173-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247167/
https://www.ncbi.nlm.nih.gov/pubmed/34193311
http://dx.doi.org/10.1186/s43058-021-00173-2

Ejemplares similares